References
- High Cholesterol Facts. NY: CDC (Centers for disease control and prevention).https://www.cdc.gov/cholesterol/facts.htm. Published September 8, 2020; Accessed 2020 Nov 1
- Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;139:2019.
- Omudhome Ogbru PD. Bile acid sequestrants: drug facts, side effects and dosing. MedicineNet. https://www.medicinenet.com/bile_acid_sequestrants/article.htm Published July 2, 2019. Accessed 2020 Dec 17
- Weintraub WS, Gidding SS. PCSK9 Inhibitors: a technology worth paying for? Switzerland: PharmacoEconomics. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816976/ Published March 2016; Accessed 2020 Nov 1
- PCSK9 inhibitors: pharmacology, adverse effects, and use. UpToDate. https://www.uptodate.com/contents/pcsk9-inhibitors-pharmacology-adverse-effects-and-use Accessed 2020 Nov 1.
- Danaf JA, Martin SS, Blumenthal RS. Ezetimibe: the Lower the LDL-C, the Better (Even for Total Cardiovascular Events). Am Coll Cardiol. [2020 Nov 30]. Accessed: https://www.acc.org/latest-in-cardiology/articles/2016/03/09/06/50/ezetimibe-the-lower-the-ldlc-the-better
- Drugs@FDA: FDA-Approved Drugs. accessdata.fda.gov.https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process Accessed 2020 Nov 1.
- NEXLETOL (bempedoic acid) tablets, for oral use. Initial U.S. Approval: 2020 . https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf Accessed 2020 Nov 1.
- NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe): Mechanism of Action. NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) | mechanism of Action. https://www.nexletolhcp.com/mechanism-of-action?gclid=Cj0KCQjwwuD7BRDBARIsAK_5YhXrMgm3Ht-rEd_LZQiXQPStZtn5l8Bw7rdMnkwWwZQehdiHz4hJXZUaApZtEALw_wcB Accessed 2020 Nov 1.
- Center for drug evaluation and research - application number: 211616Orig1s000 Maryland: FDA, Accessdata. fda.gov.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211616Orig1s000IntegratedR.pdf. Published June 14, 2019. Accessed 2020 Nov 1
- Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380(380):1022–1032.
- Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the clear wisdom randomized clinical trial [published correction appears in the Journal of the American Medical Association (JAMA). 2020;323(11):1095–1096.
- Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277(277):195–203.
- Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7). DOI:10.1161/JAHA.118.011662.
- Assessment of the long-term safety and efficacy of bempedoic acid (CLEAR Harmony OLE) - full text view. Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03067441. Accessed 2020 Dec 1.
- Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo - Full Text View. Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo - full text view - clinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02993406 Accessed 2020 Dec 1.
- Wang X, Luo S, He C, et al. Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Kardiol Pol. 2019;77(2):2.
- Khan MU, Khan MZ, Munir MB, et al. Meta-analysis of the safety and efficacy of bempedoic acid. The American Journal of Cardiology. 2020;131:130–132.
- Cicero AFG, Fogacci F, Hernandez AV, et al. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020;17(7):e1003121.
- Bhagavathula AS, Al Matrooshi NO, Clark CCT, et al. Bempedoic acid and ezetimibe for the treatment of hypercholesterolemia: a systematic review and meta-analysis of randomized phase II/III trials. Clin Drug Investig. 2021;41(1):19–28.
- Minno AD, Lupoli R, Calcaterra I, et al. J Am Heart Assoc. 2020 efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta‐analysis of randomized controlled trials. [online] Available at: https://www.ahajournals.org/doi/10.1161/JAHA.119.016262 [ Accessed 2020 Sept 4
- Weber C, Hundelshausen VP.CANTOS trial validates the inflammatory pathogenesis of Atherosclerosis. Circ Res. https://www.ahajournals.org/doi/full/10.1161/circresaha.117.311984 Published October 27, 2017. Accessed 2021 Feb 28
- Khan SU, Rahman H, Okunrintemi V, et al. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8(7). DOI:10.1161/JAHA.118.011581.
- www.heart.org. 2020. Cholesterol Medications. [online] Available at: https://www.heart.org/en/health-topics/cholesterol/prevention-and-treatment-of-high-cholesterol-hyperlipidemia/cholesterol-medications [ Accessed 2020 Nov 25].
- Rees V. EC approves Nilemdo™ (bempedoic acid) for lowering cholesterol. European Pharmaceutical Review. https://www.europeanpharmaceuticalreview.com/news/116601/ec-approves-nilemdo-bempedoic-acid-for-lowering-cholesterol/#:~:text=The%20European%20Commission%20(EC)%20has,LDL%2DC)%20lowering%20medicine Published April 9, 2020; Accessed 2021 Jan 26
- Esperion announces agreement with otsuka pharmaceutical co., ltd. for development and commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) tablets in japan. CA: GlobeNewswire news room. https://www.globenewswire.com/news-release/2020/04/20/2018490/0/en/Esperion-Announces-Agreement-with-Otsuka-Pharmaceutical-Co-Ltd-for-Development-and-Commercialization-of-NEXLETOL-bempedoic-acid-and-NEXLIZET-bempedoic-acid-and-ezetimibe-Tablets-in.html Published April 20, 2020; Accessed 2021 Jan 26
- Karatasakis A. Aris Karatasakis VA North Texas Health Care System and University of Texas Southwestern Medical Center, Danek BA, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta‐analysis of 35 randomized controlled trials. J Am Heart Assoc. https://www.ahajournals.org/doi/10.1161/JAHA.117.006910 Published December 9, 2017. Accessed 2020 Dec 24
- Doshi JA, Jalpa A, Puckett JT, et al. “Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across us private and public payers.” Circulation: Cardiovascular Quality and Outcomes. https://www.ahajournals.org/doi/full/10.1161/circoutcomes.117.003939 Published January 11, 2018. Accessed 2020 Dec 26.
- Bempedoic acid. Lexi-Drugs. OH: Lexi-Comp, Inc. Updated October 24, 2020;https://online-lexi-com.ezproxy.uttyler.edu/lco/action/doc/retrieve/docid/patch_f/6924026?cesid=319SU7cRouf&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dbempedoic%252520acid%26t%3Dname%26va%3Dbempedoic%252520acid Accessed 2020 Nov 20
- www.heart.org. 2020. Cholesterol medications. [online] Available at: https://www.heart.org/en/health-topics/cholesterol/prevention-and-treatment-of-high-cholesterol-hyperlipidemia/cholesterol-medications [ Accessed 2020 Aug 25] .
- Understanding your cholesterol report. [online] WebMD. Available at: https://www.webmd.com/cholesterol-management/understanding-your-cholesterol-report [ Accessed 2020 Aug 25]